Michelle Chen
CEO
B
BioSyngen
The startup is developing chimeric antigen receptor (CAR) T-cell therapies specifically targeting solid tumors and lymphoproliferative diseases. This approach addresses the need for effective treatments in complex cancer cases, enabling patients to receive tailored therapies that improve their quality of life.
- Biotechnology
Updated 21 months ago
Funding
Raised to date
$86.4MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup is developing chimeric antigen receptor (CAR) T-cell therapies specifically targeting solid tumors and lymphoproliferative diseases. This approach addresses the need for effective treatments in complex cancer cases, enabling patients to receive tailored therapies that improve their quality of life.